Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer

Cancer Cell

Volumn 4, Issue 3, 2003, Pages 209-221

  Wang, Shunyou ^a   Gao, Jing ^a   Lei, Qunying ^a   Rozengurt, Nora ^a   Pritchard, Colin ^b   Jiao, Jing ^a   Thomas, George V ^a   Li, Gang ^a   Roy Burman, Pradip ^c   Nelson, Peter S ^b   Liu, Xin ^a   Wu, Hong ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER MODEL; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; GENE DELETION; GENE FUNCTION; METASTASIS; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; TUMOR SUPPRESSOR GENE;

ANIMALIA; MURINAE;

EID: 10744222860     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(03)00215-0     Document Type: Article

References (80)

1. Aaltomaa S., Eskelinen M., Lipponen P. Expression of cyclin A and D proteins in prostate cancer and their relation to clinopathological variables and patient survival. Prostate. 38:1999;175-182.
2. Abdulkadir S.A., Magee J.A., Peters T.J., Kallem Z., Naughton C.K., Humphrey P.A., Milbrand J. Conditional loss of Nkx3.1 in adult mice induces prostatic intraepithelial neoplasia. Mol. Cell. Biol. 22:2002;1495-1503.
3. Backman S., Stambolic V., Mak T. PTEN function in mammalian cell size regulation. Curr. Opin. Neurobiol. 12:2002;516-522.
4. Bhatia-Gaur R., Donjacour A.A., Sciavolino P.J., Kim M., Desai N., Young P., Norton C.R., Gridley T., Cardiff R.D., Cunha G.R., Abate-Shen C., Shen M.M. Roles for Nkx3.1 in prostate development and cancer. Genes Dev. 13:1999;966-977.
5. Bose S., Crane A., Hibshoosh H., Mansukhani M., Sandweis L., Parsons R. Reduced expression of PTEN correlates with breast cancer progression. Hum. Pathol. 33:2002;405-409.
6. Bowen C., Bubendorf L., Voeller H.J., Slack R., Willi N., Sauter G., Gasser T.C., Koivisto P., Lack E.E., Kononen J.et al. Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res. 60:2000;6111-6115.
7. Bubendorf L., Schopfer A., Wagner U., Sauter G., Moch H., Willi N., Gasser T.C., Mihatsch M.J. Metastatic patterns of prostate cancer. an autopsy study of 1,589 patients Hum. Pathol. 31:2000;578-583.
8. Bui M., Reiter R.E. Stem cell genes in androgen-independent prostate cancer. Cancer Metastasis Rev. 17:1998;391-399.
9. Cantley L.C., Neel B.G. New insights into tumor suppression. PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway Proc. Natl. Acad. Sci. USA. 96:1999;4240-4245.
10. Cher M.L. Mechanisms governing bone metastasis in prostate cancer. Curr. Opin. Urol. 11:2001;483-488.
11. Clark E.A., Golub T.R., Lander E.S., Hynes R.O. Genomic analysis of metastasis reveals an essential role for RhoC. Nature. 406:2000;532-535.
12. Craft N., Chhor C., Tran C., Belldegrun A., DeKernion J., Witte O.N., Said J., Reiter R.E., Sawyers C.L. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res. 59:1999;5030-5036.
13. Dahia P.L. PTEN, a unique tumor suppressor gene. Endocr. Relat. Cancer. 7:2000;115-129.
14. DeMarzo A.M., Nelson W.G., Isaacs W.B., Epstein J.I. Pathological and molecular aspects of prostate cancer. Lancet. 361:2003;955-964.
15. Denis L., Murphy G.P. Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer. 72:1993;3888-3895.
16. Denmeade S.R., Isaacs J.T. A history of prostate cancer treatment. Nat. Rev. Cancer. 2:2002;389-396.
17. Deocampo N.D., Huang H., Tindall D.J. The role of PTEN in the progression and survival of prostate cancer. Minerva Endocrinol. 28:2003;145-153.
18. Dhanasekaran S.M., Barrette T.R., Ghosh D., Shah R., Varambally S., Kurachi K., Pienta K.J., Rubin M.A., Chinnaiyan A.M. Delineation of prognostic biomarkers in prostate cancer. Nature. 412:2001;822-826.
19. Di Cristofano A., Pandolfi P.P. The multiple roles of PTEN in tumor suppression. Cell. 100:2000;387-390.
20. Di Cristofano A., Pesce B., Cordon-Cardo C., Pandolfi P.P. Pten is essential for embryonic development and tumour suppression. Nat. Genet. 19:1998;348-355.
21. Di Cristofano A., De Acetis M., Koff A., Cordon-Cardo C., Pandolfi P.P. Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat. Genet. 27:2001;222-224.
22. Dubey P., Wu H., Reiter R.E., Witte O.N. Alternative pathways to prostate carcinoma activate prostate stem cell antigen expression. Cancer Res. 61:2001;3256-3261.
23. Dudoit, S., Yang, Y.H., Callow, M.J., and Speed, T.J. (2000). Technical report (Department of Biostatistics, University of California at Berkeley).
24. Fidler I.J., Kripke M.L. Metastasis results from preexisting variant cells within a malignant tumor. Science. 197:1977;893-895.
25. Fidler I.J., Kripke M.L. Genomic analysis of primary tumors does not address the prevalence of metastatic cells in the population. Nat. Genet. 34:2003;23.
26. Freeman D.J., Li A.G., Wei G., Li H.H., Kertesz N., Lesche R., Whale A.D., Martinez-Diaz H., Rozengurt N., Cardiff R.D.et al. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell. 3:2003;117-130.
27. Gao X., Neufeld T.P., Pan D. Drosophila PTEN regulates cell growth and proliferation through PI3K-dependent and -independent pathways. Dev. Biol. 221:2000;404-418.
28. Garabedian E.M., Humphrey P.A., Gordon J.I. A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells. Proc. Natl. Acad. Sci. USA. 95:1998;15382-15387.
29. Greenberg N.M., DeMayo F., Finegold M.J., Medina D., Tilley W.D., Aspinall J.O., Cunha G.R., Donjacour A.A., Matusik R.J., Rosen J.M. Prostate cancer in a transgenic mouse. Proc. Natl. Acad. Sci. USA. 92:1995;3439-3443.
30. Groszer M., Erickson R., Scripture-Adams D.D., Lesche R., Trumpp A., Zack J.A., Kornblum H.I., Liu X., Wu H. Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo. Science. 294:2001;2186-2189.
31. Gu Z., Thomas G., Yamashiro J., Shintaku I.P., Dorey F., Raitano A., Witte O.N., Said J.W., Loda M., Reiter R.E. Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene. 19:2000;1288-1296.
32. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 100:2000;57-70.
33. Harada M., Iida M., Yamaguchi M., Shida K. Analysis of bone metastasis of prostatic adenocarcinoma in 137 autopsy cases. Adv. Exp. Med. Biol. 324:1992;173-182.
34. He W.W., Sciavolino P.J., Wing J., Augustus M., Hudson P., Meissner P.S., Curtis R.T., Shell B.K., Bostwick D.G., Tindall D.J.et al. A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics. 43:1997;69-77.
35. Hotte S.J., Winquist E.W., Stitt L., Wilson S.M., Chambers A.F. Plasma osteopontin. associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma Cancer. 95:2002;506-512.
36. Huggins C., Stephens R., Hodges C.V. Studies on prostate cancer. 2. The effects of castration on advanced carcinoma of the prostate gland Arch. Surg. 43:1941;209.
37. Isaacs J.T. The biology of hormone refractory prostate cancer. Why does it develop? Urol. Clin. North Am. 26:1999;263-273.
38. July L.V., Akbari M., Zellweger T., Jones E.C., Goldenberg S.L., Gleave M.E. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate. 50:2002;179-188.
39. Kasper S., Sheppard P.C., Yan Y., Pettigrew N., Borowsky A.D., Prins G.S., Dodd J.G., Duckworth M.L., Matusik R.J. Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice. a model for prostate cancer Lab. Invest. 78:1998;319-333.
40. Kim M.J., Cardiff R.D., Desai N., Banach-Petrosky W.A., Parsons R., Shen M.M., Abate-Shen C. Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc. Natl. Acad. Sci. USA. 99:2002;2884-2889.
41. Kwabi-Addo B., Giri D., Schmidt K., Podsypanina K., Parsons R., Greenberg N., Ittmann M. Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc. Natl. Acad. Sci. USA. 98:2001;11563-11568.
42. Landis, S.H., Murray, T., Bolden, S., and Wingo, P.A. (1999). Cancer Statistics, Vol 49. (CA: Cancer J. Clin.), 8-31.
43. Lesche R., Groszer M., Gao J., Wang Y., Messing A., Liu X., Wu H. Cre/loxp-mediated inactivation of the murine Pten tumor suppressor gene. Genesis. 32:2002;148-149.
44. Li P., Lee H., Guo S., Unterman T.G., Jenster G., Bai W. AKT-independent protection of prostate cancer cells from apoptosis mediated through complex formation between the androgen receptor and FKHR. Mol. Cell. Biol. 23:2003;104-118.
45. Liaw D., Marsh D.J., Li J., Dahia P.L., Wang S.I., Zheng Z., Bose S., Call K.M., Tsou H.C., Peacocke M.et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet. 16:1997;64-67.
46. Lin H.K., Wang L., Hu Y.C., Altuwaijri S., Chang C. Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO J. 21:2002;4037-4048.
47. Maehama T., Taylor G.S., Dixon J.E. PTEN and myotubularin. Novel phosphoinositide phosphatases Annu. Rev. Biochem. 70:2001;247-279.
48. Magee J.A., Abdulkadir S.A., Milbrandt J. Haploinsufficiency at the Nkx3.1 locus. A paradigm for stochastic, dosage-sensitive gene regulation during tumor initiation. Cancer Cell. 3:2003;273-283.
49. Majumder P.K., Yeh J.J., George D.J., Febbo P.G., Kum J., Xue Q., Bikoff R., Ma H., Kantoff P.W., Golub T.R.et al. Prostate intraepithelial neoplasia induced by prostate restricted Akt activation. the MPAKT model Proc. Natl. Acad. Sci. USA. 100:2003;7841-7846.
50. Manin M., Baron S., Goossens K., Beaudoin C., Jean C., Veyssiere G., Verhoeven G., Morel L. Androgen receptor expression is regulated by the phosphoinositide 3-kinase/Akt pathway in normal and tumoral epithelial cells. Biochem. J. 366:2002;729-736.
51. Marsh D.J., Kum J.B., Lunetta K.L., Bennett M.J., Gorlin R.J., Ahmed S.F., Bodurtha J., Crowe C., Curtis M.A., Dasouki M.et al. PTEN mutation spectrum and genotype-phenotype correlations in Bannayan- Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum. Mol. Genet. 8:1999;1461-1472.
52. Masumori N., Thomas T.Z., Chaurand P., Case T., Paul M., Kasper S., Caprioli R.M., Tsukamoto T., Shappell S.B., Matusik R.J. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. Cancer Res. 61:2001;2239-2249.
53. Mousses S., Bubendorf L., Wagner U., Hostetter G., Kononen J., Cornelison R., Goldberger N., Elkahloun A.G., Willi N., Koivisto P.et al. Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays. Cancer Res. 62:2002;1256-1260.
54. Mundy G.R. Metastasis to bone. causes, consequences and therapeutic opportunities Nat. Rev. Cancer. 2:2002;584-593.
55. Nelson P.S., Pritchard C., Abbott D., Clegg N. The human (PEDB) and mouse (mPEDB) prostate expression databases. Nucleic Acids Res. 30:2002;218-220.
56. Podsypanina K., Ellenson L.H., Nemes A., Gu J., Tamura M., Yamada K.M., Cordon-Cardo C., Catoretti G., Fisher P.E., Parsons R. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc. Natl. Acad. Sci. USA. 96:1999;1563-1568.
57. Powell W.C., Cardiff R.D., Cohen M.B., Miller G.J., Roy-Burman P. Mouse strains for prostate tumorigenesis based on genes altered in human prostate cancer. Curr. Drug Targets. 4:2003;263-279.
58. Pritchard C.C., Hsu L., Delrow J., Nelson P.S. Project normal. defining normal variance in mouse gene expression Proc. Natl. Acad. Sci. USA. 98:2001;13266-13271.
59. Ramaswamy S., Ross K.N., Lander E.S., Golub T.R. A molecular signature of metastasis in primary solid tumors. Nat. Genet. 33:2003;49-54.
60. Reiter R.E., Gu Z., Watabe T., Thomas G., Szigeti K., Davis E., Wahl M., Nisitani S., Yamashiro J., Le Beau M.M.et al. Prostate stem cell antigen. a cell surface marker overexpressed in prostate cancer Proc. Natl. Acad. Sci. USA. 95:1998;1735-1740.
61. Sciarra A., Mariotti G., Gentile V., Voria G., Pastore A., Monti S., Di Silverio F. Neuroendocrine differentiation in human prostate tissue. is it detectable and treatable? BJU Int. 91:2003;438-445.
62. Sellers W.R., Sawyers C.L. Somatic Genetics of Prostate Cancer. Oncogenes and Tumore Suppressors:2002;Lippincott Williams & Wilkins, Philadelphia.
63. Stambolic V., Suzuki A., de la Pompa J.L., Brothers G.M., Mirtsos C., Sasaki T., Ruland J., Penninger J.M., Siderovski D.P., Mak T.W. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 95:1998;29-39.
64. Stambolic V., Tsao M.S., Macpherson D., Suzuki A., Chapman W.B., Mak T.W. High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice. Cancer Res. 60:2000;3605-3611.
65. Steinberg J., Oyasu R., Lang S., Sintich S., Rademaker A., Lee C., Kozlowski J.M., Sensibar J.A. Intracellular levels of SGP-2 (Clusterin) correlate with tumor grade in prostate cancer. Clin. Cancer Res. 3:1997;1707-1711.
66. Sun H., Lesche R., Li D.M., Liliental J., Zhang H., Gao J., Gavrilova N., Mueller B., Liu X., Wu H. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/ protein kinase B signaling pathway. Proc. Natl. Acad. Sci. USA. 96:1999;6199-6204.
67. Sun H., Enomoto T., Shroyer K.R., Ozaki K., Fujita M., Ueda Y., Nakashima R., Kuragaki C., Ueda G., Murata Y. Clonal analysis and mutations in the PTEN and the K-ras genes in endometrial hyperplasia. Diagn. Mol. Pathol. 11:2002;204-211.
68. Suzuki A., de la Pompa J.L., Stambolic V., Elia A.J., Sasaki T., del Barco Barrantes I., Ho A., Wakeham A., Itie A., Khoo W.et al. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr. Biol. 8:1998;1169-1178. a.
69. Suzuki H., Freije D., Nusskern D.R., Okami K., Cairns P., Sidransky D., Isaacs W.B., Bova G.S. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res. 58:1998;204-209. b.
70. Tanaka M., Komuro I., Inagaki H., Jenkins N.A., Copeland N.G., Izumo S. Nkx3.1, a murine homolog of Drosophila bagpipe, regulates epithelial ductal branching and proliferation of the prostate and palatine glands. Dev. Dyn. 219:2000;248-260.
71. Thalmann G.N., Sikes R.A., Devoll R.E., Kiefer J.A., Markwalder R., Klima I., Farach-Carson C.M., Studer U.E., Chung L.W. Osteopontin. possible role in prostate cancer progression Clin. Cancer Res. 5:1999;2271-2277.
72. Tusher V.G., Tibshirani R., Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. USA. 98:2001;5116-5121.
73. van 't Veer L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A., Mao M., Peterse H.L., van der Kooy K., Marton M.J., Witteveen A.T.et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 415:2002;530-536.
74. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer. 2:2002;489-501.
75. Wang J.Y., Huang T.J., Chen F.M., Hsieh M.C., Lin S.R., Hou M.F., Hsieh J.S. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in advanced gastric carcinomas. Virchows Arch. 442:2003;437-443.
76. Weng L., Brown J., Eng C. PTEN induces apoptosis and cell cycle arrest through phosphoinositol-3-kinase/Akt-dependent and -independent pathways. Hum. Mol. Genet. 10:2001;237-242.
77. Wu X., Senechal K., Neshat M.S., Whang Y.E., Sawyers C.L. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc. Natl. Acad. Sci. USA. 95:1998;15587-15591.
78. Wu X., Wu J., Huang J., Powell W.C., Zhang J., Matusik R.J., Sangiorgi F.O., Maxson R.E., Sucov H.M., Roy-Burman P. Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech. Dev. 101:2001;61-69.
79. You M.J., Castrillon D.H., Bastian B.C., O'Hagan R.C., Bosenberg M.W., Parsons R., Chin L., DePinho R.A. Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice. Proc. Natl. Acad. Sci. USA. 99:2002;1455-1460.
80. Zhou X.P., Loukola A., Salovaara R., Nystrom-Lahti M., Peltomaki P., de la Chapelle A., Aaltonen L.A., Eng C. PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers. Am. J. Pathol. 161:2002;439-447.